Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 RedHill and Cosmo Strengthen Manufacturing Agreements | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

RedHill and Cosmo Strengthen Manufacturing Agreements

Secures manufacturing capacity of Movantik for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

RedHill Biopharma has entered agreements with Cosmo Pharmaceuticals to manufacture two key products: RedHill’s largest selling product in the U.S., Movantik, and RHB-204, currently in a Phase 3 U.S. study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease.
 
“Movantik is currently our biggest commercial product,” said Steven Thomasian, vice president of supply chain management, RedHill Biopharma. “This agreement strengthens our qualified supply base and capacity moving forward and solidifies our ongoing strategic relationship with Cosmo.”
 
Davide Malavasi, Cosmo’s head of manufacturing, said, “We are happy to strengthen our partnership with RedHill with the manufacturing of these two important products and therefore to further expand Cosmo’s production capacities and capabilities.”
 
Movantik is the leading prescribed oral peripherally acting mu-opioid receptor antagonist (PAMORA) in the U.S. specifically designed to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. OIC is the most common and debilitating gastrointestinal adverse effect associated with opioid therapy, estimated to affect between 40-80% of the millions of patients taking chronic opioid therapy each year.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics